Cronos Group Inc vs Tenet Healthcare Corporation — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Tenet Healthcare Corporation trades at $261.07 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is far larger — about 17.8× Cronos Group Inc's market cap, and Cronos Group Inc is more actively traded (968,037 versus 428,008). Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Tenet Healthcare Corporation for 15 Days on average.
| CRON | THC | |
|---|---|---|
Market Cap | $1.18B | $20.98B |
Volume | 968,037 | 428,008 |
Sector | Health | Health |
52-Week High | $3.55 | $280.77 |
52-Week Low | $2.30 | $161.37 |
Typical Hold Time | 22 Days | 15 Days |
Enterprise Value | $387.62M | $32.06B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →